StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report report published on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

Brainstorm Cell Therapeutics stock opened at $1.19 on Wednesday. Brainstorm Cell Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $11.25. The firm has a market capitalization of $6.79 million, a price-to-earnings ratio of -0.25 and a beta of 0.74. The company’s 50 day simple moving average is $1.71 and its 200 day simple moving average is $2.03.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.